Your browser doesn't support javascript.
loading
Evaluation of the activity of cefepime/enmetazobactam against Enterobacterales bacteria collected in Europe from 2019 to 2021, including third-generation cephalosporin-resistant isolates.
Morrissey, Ian; Hawser, Stephen; Kothari, Nimmi; Dunkel, Nathalie; Quevedo, Juan; Belley, Adam; Henriksen, Anne Santerre; Attwood, Marie.
Afiliación
  • Morrissey I; Antimicrobial Focus, Sawbridgeworth, UK. Electronic address: ian@antimicrobialfocus.com.
  • Hawser S; IHMA Europe Sàrl, Monthey, Switzerland.
  • Kothari N; IHMA Europe Sàrl, Monthey, Switzerland.
  • Dunkel N; Advanz Pharma UK, London, UK.
  • Quevedo J; Advanz Pharma UK, London, UK.
  • Belley A; Allecra Therapeutics SAS, Saint-Louis, France.
  • Henriksen AS; Maxel Consulting, Jyllinge, Denmark.
  • Attwood M; Bristol Centre for Antimicrobial Research & Evaluation (BCARE), Bristol, UK.
J Glob Antimicrob Resist ; 38: 71-82, 2024 Sep.
Article en En | MEDLINE | ID: mdl-38723712
ABSTRACT

OBJECTIVES:

This study was performed to investigate the activity of the novel ß-lactam/ß-lactamase inhibitor combination cefepime/enmetazobactam, against recently circulating Enterobacterales isolates from Europe from 2019 to 2021.

METHODS:

A total of 2627 isolates were collected, and antimicrobial susceptibility was determined according to the European Committee on Antimicrobial Susceptibility Testing guidelines. Isolates with phenotypic resistance to ceftriaxone and ceftazidime (but susceptible to meropenem) and isolates nonsusceptible to meropenem were screened for the presence of ß-lactamases.

RESULTS:

Overall, susceptibility to third-generation cephalosporins was 77%, and 97.3% were susceptible to meropenem. Cefepime/enmetazobactam susceptibility was 97.9% (72% of these isolates were Klebsiella pneumoniae from Italy), compared with 80.0% susceptibility to piperacillin/tazobactam and 99.4% to ceftazidime/avibactam. A total of 320 isolates (12.2%) were resistant to third-generation cephalosporins but susceptible to meropenem, and virtually all (96.3%) carried an extended-spectrum ß-lactamase with or without an AmpC and these were all susceptible to cefepime/enmetazobactam. Most meropenem-nonsusceptible isolates carried a KPC (68%), which were not inhibited by cefepime/enmetazobactam but were inhibited by ceftazidime/avibactam. Additionally, most meropenem-nonsusceptible isolates carrying OXA-48 (9/12 isolates) were susceptible to cefepime/enmetazobactam.

CONCLUSIONS:

Cefepime/enmetazobactam was highly active against Enterobacterales isolates, especially those resistant to third-generation cephalosporins. These data suggest that cefepime/enmetazobactam could be used as a carbapenem-sparing agent to replace piperacillin/tazobactam.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Pruebas de Sensibilidad Microbiana / Enterobacteriaceae / Infecciones por Enterobacteriaceae / Cefepima / Antibacterianos Límite: Humans País/Región como asunto: Europa Idioma: En Revista: J Glob Antimicrob Resist Año: 2024 Tipo del documento: Article Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Pruebas de Sensibilidad Microbiana / Enterobacteriaceae / Infecciones por Enterobacteriaceae / Cefepima / Antibacterianos Límite: Humans País/Región como asunto: Europa Idioma: En Revista: J Glob Antimicrob Resist Año: 2024 Tipo del documento: Article Pais de publicación: Países Bajos